Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless "First-in-Human" Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment

被引:0
|
作者
De Bruyn, Steven [1 ]
Gachalyi, Bela [2 ]
Rojkovich, Bernadette [3 ]
Bruk, Slavomir [4 ]
Sramek, Petr [5 ]
Korkosz, Mariusz [6 ]
Krause, Krzysztof [7 ]
Schoen, Pieter [1 ]
Sargentini-Maier, Laura [1 ]
D'Artois, Joke [1 ]
Verschueren, Katrien [1 ]
De Swert, Katelijne [1 ]
Arold, Gerhard [8 ]
Holz, Josefin-Beate [1 ]
机构
[1] Ablynx NV, Zwijnaarde, Belgium
[2] Peterfy Sandor Utcai Korhaz, Budapest, Hungary
[3] Budai Irgalmasrendi Korhaz Kht, Budapest, Hungary
[4] Nemocnice Trinec, Trinec, Czech Republic
[5] Pharmaceut Res Associates CZ, Prague, Czech Republic
[6] Szpital Uniwersytecki Krakowie, Krakow, Poland
[7] Wojewodzki Szpital, Wroclaw, Poland
[8] PRA Int GmbH, Berlin, Germany
来源
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
1307
引用
收藏
页码:S561 / S561
页数:1
相关论文
共 31 条
  • [31] Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE®) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study
    Topp, Max S.
    Duell, Johannes
    Zugmaier, Gerhard
    Attal, Michel
    Moreau, Philippe
    Langer, Christian
    Kroenke, Jan
    Facon, Thierry
    Einsele, Hermann
    Munzert, Gerd
    BLOOD, 2018, 132